The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.
Menahem
Solomon
S
Hiremagalur
Balaji
B
Mudge
David
D
Toussaint
Nigel
N
Walters
Giles
G
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007275:Injections, Intravenous; D010951:Plasma Exchange; D020551:Pulse Therapy, Drug; D055502:Secondary Prevention; D016896:Treatment Outcome; D014657:Vasculitis / Q000175:diagnosis / Q000201:enzymology / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D015415:Biomarkers; D007166:Immunosuppressive Agents